Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23332739 | 1.00 | ATF4 (0.47) | ATF4KDM4ETDP1MEN1KMT2A | |
| SCHEMBL23383769 | 0.89 | ATF4 (0.58) | ATF4KDM4ETDP1MEN1KMT2A | |
| SCHEMBL23383657 | 0.88 | ATF4 (0.60) | ATF4KDM4ETDP1MEN1KMT2A | |
| SCHEMBL23332791 | 0.88 | ATF4 (0.60) | ATF4KDM4ETDP1MEN1KMT2A | |
| SCHEMBL23333256 | 0.87 | ATF4 (0.49) | ATF4KDM4ETDP1MEN1KMT2A | |
| SCHEMBL23332725 | 0.87 | ATF4 (0.48) | ATF4KDM4ETDP1MEN1KMT2A | |
| SCHEMBL25962498 | 0.87 | ATF4 (0.48) | ATF4KDM4ETDP1MEN1KMT2A | |
| SCHEMBL23333297 | 0.87 | ATF4 (0.51) | ATF4 | |
| SCHEMBL23384143 | 0.87 | ATF4 (0.59) | ATF4KDM4ETDP1MEN1KMT2A | |
| SCHEMBL23182908 | 0.86 | KDM4E (0.54) | ATF4KDM4ETDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | ATF4 118/4885KDM4E 2956/4885TDP1 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.